Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latigo Biotherapeutics, Inc.

NASDAQ: LTGO · Life Sciences · 2 alerts · CIK 2056611

Share price
$12.60Close, Nov 16
Market cap
$835M
Shares outstanding
66.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Latigo Biotherapeutics, Inc. filings on SEC EDGAR ↗

7:24 AM ET 10-Q
Financial Results

Latigo Biotherapeutics Q3 2026 Results: Net Loss of $20.9M, Loss Narrows

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company that has incurred an accumulated deficit of $312.8 million as of September 30, 2026. The company is focused on developing its lead product candidates, onzotrigine and LTG-321, and anticipates continued substantial losses as it funds research and development.

Key figure
Net loss $20.9M
7:09 AM ET 8-K
Financial Results

Latigo Biotherapeutics Financial Results

Latigo Biotherapeutics reported Q3 2026 financial results, ending the period with $401 million in cash to fund operations into 2029. The company also announced the appointment of Todd Smith as President and CEO, replacing Nima Farzan, and updated its Phase 3 onzotrigine trial design to include a Percocet comparator arm.

Term
Q3 2026

“With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program.”

Todd N. Smith, president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.